Marlborough pharmaceutical company Sepracor Inc. says a phase III study of its nasal aerosol hay fever treatment had positive results.
The company said the treatment, OMNARIS HFA, reduced nasal symptoms and red eye and tearing among hay fever sufferers over 24 hours.
If it is successfully developed and gets FDA approval, the product could be the first available hay fever treatment to use an HFA inhaler, which is considered a safer alternative to traditional CFC inhalers, Sepracor said. It said OMNARIS could be a significant growth product for the company.
